WHO ICTRP trial
Adaptive study of IL-2 dose frequency on regulatory T cells in type 1 diabetes
ISRCTN40319192 · International Standard Randomised Controlled Trial Number (ISRCTN) · Not Recruiting
Key facts
| Trial ID | ISRCTN40319192 |
|---|---|
| Public title | Adaptive study of IL-2 dose frequency on regulatory T cells in type 1 diabetes |
| Scientific title | Adaptive study of IL-2 dose frequency on regulatory T cells in type 1 diabetes (DILfrequency) |
| Primary sponsor | Cambridge University Hospitals NHS Foundation trust & University of Cambridge (UK) |
| Registry | International Standard Randomised Controlled Trial Number (ISRCTN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Phase I/II |
| Countries | United Kingdom |
| Conditions | Topic: Diabetes, Primary Care; Subtopic: Type 1 , Diabetes; Disease: Diabetic Control, All Diseases, Education, Metabolic Nutritional, Metabolic, Endocrine |
| Interventions | Aldesleukin will be administered subcutaneously at varying doses and frequencies for a period of up to 98 days from first administration depending on the treatment assignment. The maximum dose allowed is 0.6 X 10^6 IU/m2. |
| Registration date | Oct 29, 2014 |
| Target size | 36 |
| Secondary IDs | NCT02265809;17571 |
| Registry page | isrctn.com |
At a glance
- Yes Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: